Please use this identifier to cite or link to this item:
Title: Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study.
Authors: Alcala-Diaz, Juan F
Limia-Perez, Laura
Gomez-Huelgas, Ricardo
Martin-Escalante, Maria D
Cortes-Rodriguez, Begoña
Zambrana-Garcia, Jose L
Entrenas-Castillo, Marta
Perez-Caballero, Ana I
López-Carmona, Maria D
Garcia-Alegria, Javier
Lozano Rodríguez-Mancheño, Aquiles
Arenas-de Larriva, Maria Del Sol
Pérez-Belmonte, Luis M
Jungreis, Irwin
Bouillon, Roger
Quesada-Gomez, Jose Manual
Lopez-Miranda, Jose
Keywords: COVID-19;COVID-19 drug treatment;SARS-CoV-2;calcifediol;vitamin D
metadata.dc.subject.mesh: Aged
Aged, 80 and over
Hospital Mortality
Middle Aged
Retrospective Studies
Severity of Illness Index
COVID-19 Drug Treatment
Issue Date: 21-May-2021
Abstract: Calcifediol has been proposed as a potential treatment for COVID-19 patients. To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Retrospective, multicenter, open, non-randomized cohort study. Hospitalized care. Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. In-hospital mortality during the first 30 days after admission. A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.
metadata.dc.identifier.doi: 10.3390/nu13061760
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC8224356.pdf1,09 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons